Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table A. Dosing Regimens for the Drugs Recommended for the Treatment of MIS-C

Last Updated: February 24, 2022

Table A. Dosing Regimens for the Drugs Recommended for the Treatment of MIS-C
Drug Name Dosing Regimens

For infants, children, and adolescents unless otherwise specified. The doses listed are for FDA-approved indications for other diseases or from reported experiences or clinical trials.

Adverse EventsMonitoring Parameters
Intravenous Immunoglobulin
  • IVIG 2 g/kg IBW/dose (up to a maximum total dose of 100 g) IV for 1 dose
  • In the event of cardiac dysfunction or fluid overload, consider administering IVIG in divided doses (1 g/kg IBW/dose IV every 24 hours for 2 doses).
  • Hypersensitivity
  • Fever
  • Chills
  • Flushing
  • Hemolytic anemia
  • Renal function
  • Urine output
  • CBC with differential
  • Infusion or injection-related AE
  • Anaphylaxis
  • Signs and symptoms of hemolysis
Methylprednisolone
  • Methylprednisolone 1 to 2 mg/kg/dose IV every 12 hours
  • If the patient with MIS-C does not respond to 1–2 mg/kg/dose IV every 12 hours, increase the dose to 10–30 mg/kg/day (up to maximum of 1,000 mg/day) IV for 1 to 3 days.
  • Adrenal suppression
  • Hyperglycemia
  • Sodium retention
  • Fluid retention
  • Leukocytosis
  • Immune suppression
  • Blood pressure
  • CBC with differential
  • BMP
Anakinra Anakinra 5–10 mg/kg/day IV (preferred) or SUBQ in 1 to 4 divided doses
  • Headache
  • Fever
  • Hypersensitivity
  • Immune suppression
  • Transaminitis
  • CBC with differential
  • LFTs
  • Scr
Infliximab Infliximab 5–10 mg/kg/dose IV for 1 dose
  • Infusion-related reaction
  • Headache
  • Immune suppression
  • Monitor vital signs every 2–10 minutes during infusion
  • CBC with differential
Aspirin Aspirin 3–5 mg/kg/dose (up to maximum of 81 mg/dose) PO once daily
  • Gastrointestinal ulcers
  • Hypersensitivity
  • Renal dysfunction
  • Signs or symptoms of bleeding
  • Renal function
Enoxaparin Enoxaparin Prophylaxis
Aged >2 Months to <18 Years:
  • 0.5 mg/kg/dose (up to maximum of 30 mg/dose) SUBQ every 12 hours

Enoxaparin Treatment
Aged >2 Months to <18 Years:

  • 1 mg/kg/dose SUBQ every 12 hours
  • Monitor antifactor Xa activity (treatment goal: 0.5 to 1).
  • Increased risk of bleeding
  • Thrombocytopenia
  • CBC with differential
  • Renal function